Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4861601 | 0.87 | ALDH1A1 (0.48) | FFAR1ALDH1A1LMNAMAPT | |
| SCHEMBL25223765 | 0.86 | TDP1 (0.52) | FFAR1LMNANLRP3CXCR1CXCR2 | |
| SCHEMBL1549815 | 0.86 | ESR1 (0.54) | ALDH1A1ESR1MAPTCASP3CASP7 | |
| SCHEMBL4860326 | 0.83 | ALDH1A1 (0.62) | ALDH1A1LMNAMAPT | |
| SCHEMBL4856511 | 0.83 | RORC (0.55) | ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL1549432 | 0.83 | KDM4E (0.45) | ALDH1A1ESR1MAPTCASP3CASP7 | |
| SCHEMBL9272260 | 0.82 | ALDH1A1 (0.50) | FFAR1ALDH1A1LMNANLRP3ESR1 | |
| SCHEMBL13239750 | 0.82 | LMNA (0.58) | ALDH1A1LMNANLRP3ESR1MAPT | |
| SCHEMBL29536561 | 0.82 | LMNA (0.58) | ALDH1A1LMNANLRP3ESR1MAPT | |
| SCHEMBL4854202 | 0.82 | FFAR1 (0.47) | FFAR1LMNANLRP3CXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345067-B2 | Aniline derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1636198-A1 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111020-A1 | ANILINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20040248951-A1 | Aniline derivatives, their manufacture and use as pharmaceuticals | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248951-A1 | Aniline derivatives, their manufacture and use as pharmaceuticals | PPARA, PPARD, PPARG | FFAR1 24/4885ALDH1A1 464/4885LMNA 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.